Creatinine, a byproduct of muscle function, may be more sensitive in tracking SMA progression and response to treatment than ...
Positive results from its Phase III STEER study mean Novartis could boost sales of its OAV101 IT drug for spinal muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback